The CEP: a new name in the NHS' medtech purchasing evidence drive
This article was originally published in Clinica
From September 1, the Centre for Evidence-based Purchasing (CEP) replaces the UK's Device Evaluation Service (DES), following its transfer from the Medicines and Healthcare products Regulatory Agency (MHRA) to the Purchasing and Supply Agency (PaSA).
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.